International consensus updates the use of Ozempic and Mounjaro for obesity and comprehensive care

New guidelines for the treatment of obesity, focused on medications such as Ozempic, Wegovy and Mounjaro, were released in a first international consensus at the beginning of July. Experts are now focusing attention on the safe and prolonged use of these drugs, in addition to establishing clear criteria for reducing or interrupting treatment. The main discussion is no longer limited to the amount of weight lost, but rather the holistic management of the patient’s health.
A shift in focus on treating obesity with new drugs
The innovative document, the result of collaboration between the European Association for the Study of Obesity (EASO), the European Federation of the Associations of Dietitians (EFAD) and the European Coalition for People Living with Obesity (ECPO), was published in the renowned journal The Lancet Diabetes & Endocrinology. This consensus represents a significant shift in perspective: the objective of treatment is no longer exclusively weight loss. The new approach integrates nutritional monitoring, physical activity and mental health, in addition to personalizing decisions about medication dosage.
Fernando Valente, coordinator of the Diabetes Education Department of the Brazilian Diabetes Society (SBD) and director of the Diabetes Department of the Brazilian Society of Endocrinology and Metabology (SBEM), highlighted the importance of consensus. According to him, the treatment goes beyond the injection and weight reduction, focusing on quality of life and improving comorbidities associated with obesity. He also warned of the risks of weight loss without adequate monitoring, which can lead to malnutrition, decreased muscle mass and psychological suffering.
It is essential to highlight that the consensus recommendations are not mandatory rules and do not replace the individual assessment of each patient by a doctor. The authors of the text emphasize that much of the guidance combines the best available evidence with clinical experience, as there are still gaps in studies that answer all questions about these medications.
The importance of the new guidelines for patients and doctors
This new consensus offers practical guidance for doctors and patients, promoting safer and more effective long-term treatment. For patients, it means an approach that values their overall health, minimizing the risk of adverse effects and ensuring that the weight loss journey is accompanied by care for nutrition, muscle mass and psychological well-being. For healthcare professionals, the guidelines provide a framework for more informed decisions about dosage and duration of treatment, customizing management to individual needs.
Dose decisions: the maximum ceiling is not a universal rule
One of the document’s crucial messages is that achieving the maximum dose stipulated in the leaflet should not be an automatic goal for all patients. The dosage decision should be guided by each individual’s clinical response to treatment. Those who already experience good satiety, are able to lose weight satisfactorily and tolerate the medication well, often do not need higher doses.
Real-life studies cited in the consensus indicate that significant weight loss can be achieved with smaller doses when treatment is individually adjusted. Valente clarifies that patients who are very overweight, who need to lose 30 kilos or 30% of their body weight, tend to reach the maximum dose. On the other hand, individuals who have developed metabolic diseases such as diabetes, hypertension, high triglycerides, fatty liver or sleep apnea, but are not significantly overweight, may benefit from lower doses. The endocrinologist reinforces that the maximum dose is not mandatory, as therapeutic targets are adjustable for each patient.
Criteria for considering reducing or stopping medication use
The consensus addresses one of the most common doubts among users of these medications: is there an ideal time to stop? The answer is that this decision must be shared between the doctor and the patient, carefully weighing the benefits and risks involved. Reducing the dose, postponing a planned increase, taking a temporary break or suspending the medication may be appropriate in several circumstances.
The document lists a series of signs that indicate the need for medical reassessment for possible adjustment or interruption:
- Persistent nausea and vomiting;
- Difficulty maintaining good hydration;
- Too fast and uncontrolled weight loss;
- Inability to ingest sufficient nutrients;
- Clear signs of malnutrition.
It is particularly important to pay attention when the patient’s dietary intake remains below 800 calories per day for a prolonged period. Rodrigo Lamounier, director of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and member of the Brazilian Society of Endocrinology and Metabology (SBEM), adds that interrupting treatment does not always mean an error. The pause may occur because the patient has reached an adequate weight goal, because tolerance to the medication has decreased to the point of compromising adherence – a situation in which a lower dose can help maintain treatment – or due to a common sense decision, as in the case of an elderly person who has already reached a reasonable weight and for whom further loss would not be beneficial.






